Bioatla, Inc.

Verenium Corporation

Novartis Ag

Diversa Corporation

Harvard College

Dana-farber-cancer Institute Inc.

Basf Enzymes LLC

Arch Oncology, Inc.

Syngenta Participations Ag

Immutep S.a.s.

University of Pennsylvania

Corvus Pharmaceuticals, Inc.

Mmrglobal, Inc.

Bioalta, LLC

Exuma Biotech Corp.

Gerhard Johann Frey

Jay Milton Short

Hwai Wen Chang

Toby Howard Richardson

Walter Callen

Eric J Mathur

Jennifer Marie Mataraza

Carl A Miller

Kevin A Gray

Janne Samuli Kerovuo

Malgorzata Slupska

Gordon James Freeman

Arlene Helen Sharpe

Martin Kazaoka

Walter A Blattler

William A Frazier

Catherine Anne Sabatos-Peyton

Pamela T Manning

Nelson Robert Barton

Katie Kline

Brian Steer

Eileen O'Donoghue

Chrystelle Brignone

Frédéric Triebel

Alberto Alvarado

Arne Solbak

Mark Dycaico

Tsotne David Djavakhishvili

Fatima El-Farrah

Jennifer Brogdon

William James Boyle

Glenn Dranoff

Richard A Miller

Reshma Singh

Boris Engels

Bruce E Kimmel

Abraham Antonio Anderson

Emily Piccione Griffin

Thomas Todaro

Axel Trefzer

Carl Miller

Matgorzata Slupska

Frederic Triebel

Gregory Ian Frost

James Joseph Onuffer, Jr

Axel Christoph Trefzer

Robert W Karr

Tomas Todaro

Eileen O'donoghue

Tom Todaro

Gregory Frost

Isolated polypeptides having a heavy chain variable region and/or light chain variable region that specifically binds to EpCAM protein as well as antibodies and antibody fragments containing the heavy chain variable region and/or the light chain variable region that bind to EpCAM protein. Pharmaceutical compositions and kits comprising the polypeptide and antibodies and antibody fragments containing the polypeptide are also provided.

Conditionally active anti-EpCAM antibodies, antibody fragments, their immunoconjugates and uses thereof

An antibody or antigen-binding antibody fragment having a heavy chain variable region and/or a light chain variable region that specifically binds to Ror2 antigen, as well as immunoconjugates containing the heavy chain variable region and/or the light chain variable region that bind to Ror2 antigen, are provided. Pharmaceutical compositions and kits comprising the polypeptide or antibodies and antibody fragments containing the polypeptide are also provided.

Anti-Ror2 antibodies, antibody fragments, their immunoconjugates and uses thereof

Antibody molecules that specifically bind to LAG-3 and bispecific antibody molecules with a first binding specificity for LAG-3 and a second binding specificity for one of PD-1, TIM-3, CEACAM-1, CEACAM-5, PD-L1, or PD-L2, are disclosed. The anti-LAG-3 antibody molecules can be used to treat, prevent and/or diagnose cancerous or infectious disorders.

Antibody molecules to LAG-3 and uses thereof

The present disclosure provides chimeric antigen receptors that bind to Axl and Ror2, and conditionally active chimeric antigen receptors (CARs) that recognize Axl and Ror2. Furthermore, provided herein are nucleic acids encoding these CARs and methods of making and using the CARs, including methods of treating cancer, especially cancers that express Axl and/or Ror2, such as renal cell carcinoma. The present disclosure provides cells genetically modified to produce the CARs.

Chimeric antigen receptors against AXL or ROR2 and methods of use thereof

Provided are compositions and methods for treating diseases associated with expression of mesothelin comprising administering a cell that expresses a chimeric antigen receptor (CAR) specific to mesothelin in combination with a PD-L1 inhibitor.

Mesothelin chimeric antigen receptor (CAR) and antibody against PD-L1 inhibitor for combined use in anticancer therapy

Methods of generating conditionally active biologic proteins, in particular therapeutic or diagnostic proteins, which are more active at an aberrant condition than at a normal physiological condition. The methods include discovery methods using libraries of proteins and assays employing physiological concentrations of components of bodily fluids. The conditionally active biologic proteins may be further evolved, conjugated to other molecules, masked, reduced in activity by attaching a cleavable moiety. Criteria for selecting starting proteins for the discovery methods, as well as formats of the proteins are also disclosed.

Conditionally active biological proteins

An antibody or antibody fragment having a heavy chain variable region and/or light chain variable region that specifically binds to Axl protein. Immuoconjugages, pharmaceutical compositions and kits comprising the antibodies and antibody fragments are also provided. Also disclosed are methods of treating Axl-expressing cancers using the antibodies, antibody fragments, immunoconjugates and pharmaceutical compositions of the present invention.

Anti-AXL antibodies, antibody fragments and their immunoconjugates and uses thereof

A polypeptide having a heavy chain variable region and/or a light chain variable region that specifically binds to Ror2 protein, as well as antibodies and antibody fragments containing the heavy chain variable region and/or the light chain variable region, are provided. Pharmaceutical compositions and kits comprising the polypeptide or antibodies and antibody fragments containing the polypeptide are also provided.

Anti-ROR2 antibodies, antibody fragments, their immunoconjucates and uses thereof

Provided herein are, inter alia, humanized 1E9 antibodies capable of binding CD73. The humanized antibodies are useful for the treatment of cancer. Further provided are nucleic acids encoding humanized 1E9 antibodies and methods of inhibiting cell proliferation using the humanized antibodies provided herein.

Humanized anti-CD73 antibodies

Isolated polypeptides having a heavy chain variable region and/or light chain variable region that specifically binds to EpCAM protein as well as antibodies and antibody fragments containing the heavy chain variable region and/or the light chain variable region that bind to EpCAM protein Pharmaceutical compositions and kits comprising the polypeptide and antibodies and antibody fragments containing the polypeptide are also provided.

An anti-IL-22 antibody or antibody fragment that binds to both human IL-22 and a mammalian IL-22 as well as modified anti-IL-22 antibodies and antibody fragments. Pharmaceutical compositions and kits comprising the antibody or antibody fragment are also provided. Also provided are methods for treatment of various IL-22 mediated conditions and diseases.

Anti-IL-22 antibodies, antibody fragments, their immunoconjugates and uses thereof

Antibody molecules that specifically bind to PD-1 are disclosed. The anti-PD-1 antibody molecules can be used to treat, prevent and/or diagnose cancerous or infectious conditions and disorders.

Antibody molecules to PD-1 and uses thereof

A method of preparing a conditionally active polypeptide from a parent polypeptide, comprising steps of evolving a DNA encoding the parent polypeptide by increasing a net charge of the parent polypeptide using one or more techniques selected from increasing a total number of codons of charged amino acid residues in the DNA and decreasing a total number of codons of uncharged amino acid residues in the DNA to create mutant DNAs; expressing the mutant DNAs to obtain mutant polypeptides; and selecting the conditionally active polypeptide from the mutant polypeptides which exhibits a decrease in activity in a first assay at a first value of a condition compared to the same activity in a second assay at a second value of the same condition. The conditionally active polypeptide, pharmaceutical compositions containing same, nanoparticle and drug conjugates thereof and uses thereof are also provided.

Conditionally active polypeptides and methods of generating them

This disclosure relates to a method of generating conditionally active biologic proteins from wild type proteins, in particular therapeutic proteins, which are reversibly or irreversibly inactivated at the wild type normal physiological conditions. For example, evolved proteins are virtually inactive at body temperature, but are active at lower temperatures.

Mirac proteins

A polypeptide having a heavy chain variable region and/or light chain variable region that specifically binds to CTLA4 protein as well as antibodies and antibody fragments containing the heavy chain variable region and/or the light chain variable region that bind to CTLA4 protein. Pharmaceutical compositions and kits comprising the polypeptide or antibodies and antibody fragments containing the polypeptide are also provided.

Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof

Growing community of inventors

San Diego, CA, United States of America

Gerhard Johann Frey